AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.29, Bloomberg Earnings reports. The business had revenue of $7 million during the quarter, compared to analysts’ expectations of $3.45 million.
AnaptysBio (NASDAQ ANAB) traded up 1.0163% during midday trading on Friday, hitting $21.6983. 215,528 shares of the stock traded hands. The company’s market cap is $439.80 million. AnaptysBio has a one year low of $15.17 and a one year high of $30.71. The company’s 50 day moving average is $24.87 and its 200-day moving average is $24.48.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/08/11/anaptysbio-inc-nasdaqanab-issues-quarterly-earnings-results.html.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Holdings A/S Novo sold 70,706 shares of AnaptysBio stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the sale, the insider now directly owns 3,009,949 shares in the company, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 599,040 shares of company stock worth $12,926,210.
Several research firms have commented on ANAB. Stifel Nicolaus upped their price target on shares of AnaptysBio from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 2nd. Zacks Investment Research lowered shares of AnaptysBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Robert W. Baird began coverage on shares of AnaptysBio in a report on Monday, July 10th. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $34.00 price target on shares of AnaptysBio in a report on Tuesday, April 18th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. AnaptysBio has a consensus rating of “Buy” and a consensus price target of $35.60.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.